Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics

[1]  L. French,et al.  Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover , 1996, The Journal of cell biology.

[2]  M. Weller,et al.  T cell apoptosis induced by interleukin-2 deprivation or transforming growth factor-beta 2: modulation by the phosphatase inhibitors okadaic acid and calyculin A. , 1995, Experimental cell research.

[3]  D. Green,et al.  Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege , 1995, Science.

[4]  P. Kleihues,et al.  The p53 gene and its role in human brain tumors , 1995, Glia.

[5]  D. Bellgrau,et al.  A role for CD95 ligand in preventing graft rejection , 1995, Nature.

[6]  Adriano Fontana,et al.  The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T-cell apoptosis, and the immune privilege of the brain , 1995, Brain Research Reviews.

[7]  K. Scotto,et al.  Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals , 1995, Cell.

[8]  M. Weller,et al.  Local Fas/APO‐1 (CD95) ligand‐mediated tumor cell killing in vivo , 1995, European journal of immunology.

[9]  M. Weller,et al.  Fas/APO-1 gene transfer for human malignant glioma. , 1995, Cancer research.

[10]  M. Weller,et al.  Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. , 1995, The Journal of clinical investigation.

[11]  D. Green,et al.  FAS-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway. , 1995, Immunity.

[12]  John Calvin Reed.  Bcl-2: prevention of apoptosis as a mechanism of drug resistance. , 1995, Hematology/oncology clinics of North America.

[13]  C. Thompson,et al.  Apoptosis in the pathogenesis and treatment of disease , 1995, Science.

[14]  S. Nagata,et al.  The Fas death factor , 1995, Science.

[15]  D. Louis,et al.  Human gliomas with wild-type p53 express bcl-2. , 1995, Cancer research.

[16]  D. Green,et al.  Apoptosis and cancer: the failure of controls on cell death and cell survival. , 1995, Critical reviews in oncology/hematology.

[17]  R. Testi,et al.  Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase , 1994, The Journal of experimental medicine.

[18]  M. Weller,et al.  Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. , 1994, The Journal of clinical investigation.

[19]  D. Fisher.  Apoptosis in cancer therapy: Crossing the threshold , 1994, Cell.

[20]  D. Constam,et al.  Transforming growth factor‐β2 induces apoptosis of murine T cell clones without down‐regulating bcl‐2 mRNA expression , 1994, European journal of immunology.

[21]  C. Winterford,et al.  Apoptosis. Its significance in cancer and cancer Therapy , 1994, Cancer.

[22]  G. Lesser,et al.  The chemotherapy of high-grade astrocytomas. , 1994, Seminars in oncology.

[23]  Erwin G. Van Meir,et al.  Analysis of the p53 gene and its expression in human glioblastoma cells. , 1994, Cancer research.

[24]  John Calvin Reed.  Bcl-2 and the regulation of programmed cell death , 1994, The Journal of cell biology.

[25]  Takashi Suda,et al.  Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor family , 1993, Cell.

[26]  P. Graham.  Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[27]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[28]  S. Yonehara,et al.  Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. , 1993, Cancer research.

[29]  G. Deng,et al.  Suppression of apoptosis in a cytotoxic T-cell line by interleukin 2-mediated gene transcription and deregulated expression of the protooncogene bcl-2. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Louis,et al.  Comparative Study of p53 Gene and Protein Alterations in Human Astrocytic Tumors , 1993, Journal of neuropathology and experimental neurology.

[31]  J. Safrit,et al.  Sensitivity of resistant human tumor cell lines to tumor necrosis factor and adriamycin used in combination: correlation between down-regulation of tumor necrosis factor-messenger RNA induction and overcoming resistance. , 1992, Cancer research.

[32]  E. Appella,et al.  Human wild-type p53 adopts a unique conformational and phosphorylation state in vivo during growth arrest of glioblastoma cells. , 1992, Oncogene.

[33]  S. Rosenberg,et al.  Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. , 1989, Cancer research.

[34]  S. Yonehara,et al.  A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor , 1989, The Journal of experimental medicine.

[35]  H. Karasuyama,et al.  Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors , 1988, European journal of immunology.

[36]  D. S. Coffey,et al.  Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. , 1987, Cancer research.

[37]  A. Matter,et al.  Anti‐tumor effects of tumor necrosis factor in combination with chemotherapeutic agents , 1987, International journal of cancer.

[38]  R. Milroy,et al.  Potentiation of Tumour Necrosis Factor-mediated Cell Killing by VP16 on Human Ovarian Cancer Cell Lines. In vitro Results and Clinical Implications , 1993 .

[39]  P. Kleihues,et al.  Astrocytomas Expression of Fas/apo-1 during the Progression of Updated Version Citing Articles E-mail Alerts Expression of Fas/apo-1 during the Progression of Astrocytomas , 2022 .